PD-L1 Target Deep Dive
Immune Checkpoint Inhibitor Design
Biological Context
Programmed Death-Ligand 1 (PD-L1) is a critical protein expressed on the surface of many cells, including cancer cells. Under normal conditions, it acts as a “brake” on the immune system. When PD-L1 binds to the PD-1 receptor on T-cells, it signals the T-cell to become inactive.
Why it matters: Cancer cells often hijack this mechanism by over-expressing PD-L1. This allows them to “trick” the immune system into ignoring the tumor. Therapeutic antibodies against PD-L1 (atezolizumab, durvalumab) have transformed oncology, but they are large, expensive to manufacture, and can trigger autoimmune side effects — a smaller, more controllable de novo binder would be a meaningful advance.
The Goal: Design a protein binder that competes with PD-1 for the same interface on PD-L1. Blocking that interaction releases the “brake,” allowing T-cells to recognize and attack the cancer.
Interactive Structure
Explore the native interaction between PD-L1 (the target) and PD-1 (the natural binder) below.
- Target (PD-L1): Chain A — the surface we want to bind to.
- Binder (PD-1): Chain B — the natural partner we want to compete with.
- Rotate: Left-click and drag
- Zoom: Scroll wheel
- Pan: Right-click (or Ctrl+Left-click) and drag
Design Mission
Your objective is to create a de novo protein binder that binds to the same interface on PD-L1 that PD-1 currently occupies.
Target Specifications
| Feature | Detail |
|---|---|
| Target Name | PD-L1 (Programmed Death-Ligand 1) |
| PDB ID | 4ZQK |
| Target Chain | Chain A (PD-L1 IgV domain, residues 18–134) |
| Partner (to compete with) | Chain B (PD-1) |
| Published interface hotspots | A18, F19, T20, V23, D26, I54, Y56, E58, N63, Q66, V76, R113, M115, S117, G119–I126 |
| Key “hot” residues | Y56, E58, R113, M115, A121, D122, Y123 — the densest contacts with PD-1 |
These residues are every PD-L1 position with any heavy atom within 5 Å of PD-1 in the deposited 4ZQK structure — the interface as actually observed, not my guess. For steering RFdiffusion or BindCraft, you don’t need all 22; pick 3–6 “hot” residues from the highlighted set above to bias the design toward the real binding face.
Strategy Tips
- Download PDB
4ZQK. - Clean the structure: Keep Chain A (PD-L1) as the target. Remove Chain B (PD-1) and any water molecules.
- Define hotspots: When running RFdiffusion or BindCraft, pass 3–6 residues from the “hot” set (e.g.,
A56,A58,A113,A122,A123) as hotspots. This biases diffusion toward the PD-1-competing face rather than some random patch. - Validate with AlphaFold2/Chai-1: After designing a binder sequence, predict the complex and check that the designed interface residues still contact the published hotspots.
Reference
- Zak, K.M. et al. (2015). Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23, 2341–2348. doi:10.1016/j.str.2015.09.010